恆瑞醫藥(600276.SH)跌超4% 碘克沙醇注射液意外失標
格隆匯6月24日丨恆瑞醫藥盤中一度跌4.61%至67.87元,為4月中旬以來盤中最大跌幅。昨晚上海陽光醫藥採購網公示的第五批全國藥品集採擬中選結果顯示,恆瑞醫藥有三款產品中標,一款意外失標——碘克沙醇注射液落標。碘克沙醇注射液屬於造影劑的一種,造影劑是恆瑞醫藥的主營業務領域之一,2020年,恆瑞醫藥造影劑產品實現營收36.3億元,佔比13.09%,貢獻了10.78%的利潤比例。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.